-
Je něco špatně v tomto záznamu ?
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
SN. Christiansen, LM. Ørnbjerg, SH. Rasmussen, AG. Loft, J. Askling, F. Iannone, J. Zavada, B. Michelsen, M. Nissen, F. Onen, MJ. Santos, M. Pombo-Suarez, H. Relas, GJ. Macfarlane, M. Tomsic, C. Codreanu, B. Gudbjornsson, I. Van der...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
- MeSH
- inhibitory TNF terapeutické užití MeSH
- kohortové studie MeSH
- lidé MeSH
- psoriatická artritida * farmakoterapie MeSH
- spondylartritida * farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
Carol Davila University of Medicine and Pharmacy Bucharest Romania
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden
DANBIO registry Copenhagen University Hospital Rigshospitalet Glostrup Denmark
Department of Rheumatology Aarhus University Hospital Aarhus
Department of Rheumatology Amsterdam UMC Location VUmc Amsterdam Netherlands
Department of Rheumatology Centro Hospitalar do Baixo Vouga Aveiro Portugal
Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia
Department of Rheumatology Geneva University Hospital Geneva Switzerland
Department of Rheumatology University Hospital Zurich Zurich Switzerland
Division of Rheumatology and Research Diakonhjemmet Hospital Oslo
Division of Rheumatology Celal Bayar University School of Medicine Manisa Turkey
Division of Rheumatology Dokuz Eylul University School of Medicine Izmir Turkey
Hospital Garcia de Orta Rheumatology Department Reuma Pt Registry Portugal
Research Unit Sociedad Española de Reumatologia Madrid Spain
Rheumatology Service Hospital Clinico Universitario Santiago de Compostela Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024719
- 003
- CZ-PrNML
- 005
- 20221031100115.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/keab945 $2 doi
- 035 __
- $a (PubMed)34940840
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Christiansen, Sara Nysom $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $1 https://orcid.org/0000000250639932
- 245 10
- $a European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response / $c SN. Christiansen, LM. Ørnbjerg, SH. Rasmussen, AG. Loft, J. Askling, F. Iannone, J. Zavada, B. Michelsen, M. Nissen, F. Onen, MJ. Santos, M. Pombo-Suarez, H. Relas, GJ. Macfarlane, M. Tomsic, C. Codreanu, B. Gudbjornsson, I. Van der Horst-Bruinsma, D. Di Giuseppe, B. Glintborg, E. Gremese, K. Pavelka, EK. Kristianslund, A. Ciurea, N. Akkoc, A. Barcelos, C. Sánchez-Piedra, R. Peltomaa, GT. Jones, Z. Rotar, R. Ionescu, G. Grondal, MGH. Van de Sande, K. Laas, M. Østergaard, ML. Hetland
- 520 9_
- $a OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
- 650 12
- $a psoriatická artritida $x farmakoterapie $7 D015535
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a spondylartritida $x farmakoterapie $7 D025241
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $1 https://orcid.org/0000000278326831
- 700 1_
- $a Rasmussen, Simon Horskjær $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup
- 700 1_
- $a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus $u DANBIO registry, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Askling, Johan $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
- 700 1_
- $a Zavada, Jakub $u Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $u Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo $u Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway $1 https://orcid.org/0000000301032840
- 700 1_
- $a Nissen, Michael $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Onen, Fatos $u Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 700 1_
- $a Santos, Maria Jose $u Hospital Garcia de Orta, Rheumatology Department, Reuma.Pt Registry, Portugal $1 https://orcid.org/0000000279461365
- 700 1_
- $a Pombo-Suarez, Manuel $u Rheumatology Service, Hospital Clinico Universitario, Santiago de Compostela, Spain
- 700 1_
- $a Relas, Heikki $u Inflammation Center, Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- 700 1_
- $a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
- 700 1_
- $a Tomsic, Matija $u Department of Rheumatology, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Codreanu, Catalin $u "Carol Davila", University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Van der Horst-Bruinsma, Irene $u Department of Rheumatology, Amsterdam UMC, Location VUmc, Amsterdam, Netherlands
- 700 1_
- $a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000338178288
- 700 1_
- $a Glintborg, Bente $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $u DANBIO registry, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Gremese, Elisa $u Rheumatology Division, Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy $1 https://orcid.org/0000000222481058
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kristianslund, Eirik Klami $u Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo
- 700 1_
- $a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland $1 https://orcid.org/0000000278707132
- 700 1_
- $a Akkoc, Nurullah $u Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey $1 https://orcid.org/000000023718171X
- 700 1_
- $a Barcelos, Anabela $u Department of Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal
- 700 1_
- $a Sánchez-Piedra, Carlos $u Research Unit, Sociedad Española de Reumatologia, Madrid, Spain
- 700 1_
- $a Peltomaa, Ritva $u Inflammation Center, Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- 700 1_
- $a Jones, Gareth T $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000300167591
- 700 1_
- $a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Ionescu, Ruxandra $u "Carol Davila", University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Grondal, Gerdur $u Department of Rheumatology and Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland
- 700 1_
- $a Van de Sande, Marleen G H $u Department of Rheumatology and Clinical Immunology, Amsterdam institute for Infection and Immunity, Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam UMC/AMC, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Laas, Karin $u Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000033690467X
- 700 1_
- $a Hetland, Merete L $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup $u DANBIO registry, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
- 773 0_
- $w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 9 (2022), s. 3799-3807
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34940840 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100113 $b ABA008
- 999 __
- $a ok $b bmc $g 1854452 $s 1176009
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 61 $c 9 $d 3799-3807 $e 20220830 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- LZP __
- $a Pubmed-20221017
